News
Celyad Presents Clinical Update for CYAD-01 at 24th Congress of the European Hematology Association
Celyad to Present Update on allogeneic and autologous NKG2D-based CAR-T Candidates in Refractory mCRC at ESMO 21st World GI Congress
Celyad to Present Update on allogeneic and autologous NKG2D-based CAR-T Candidates in Refractory mCRC at ESMO 21st World GI Congress
Celyad’s 2019 R&D Day Highlights shRNA Platform and Pipeline of Next-generation NKG2D-based and Off-the-Shelf Non-gene Edited CAR-T Candidates
Celyad’s 2019 R&D Day Highlights shRNA Platform and Pipeline of Next-generation NKG2D-based and Off-the-Shelf Non-gene Edited CAR-T Candidates
Celyad successfully administers CYAD-01 in first patients in SHRINK and LINK trials
Celyad successfully administers CYAD-01 in first patients in SHRINK and LINK trials
Celyad publishes additional pre-clinical data in support of THINK trial
Celyad publishes additional pre-clinical data in support of THINK trial
Celyad reports promising early results at first dose level of the solid arm of the THINK trial
Celyad reports promising early results at first dose level of the solid arm of the THINK trial
Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells
Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells
Celyad initiates second dose escalation in THINK trial in first US patient
Celyad initiates second dose escalation in THINK trial in first US patient
Celyad issues a White Paper about CAR T NKR-2 current knowledge and differences with classical CAR-T technologies
Celyad issues a White Paper about CAR T NKR-2 current knowledge and differences with classical CAR-T technologies
USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells
USPTO rejects new reexamination request against Celyad’s US Patent for Production of Allogeneic TCR-Deficient CAR-T Cells
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA
Celyad obtains FDA approval to initiate the NKR-2 CAR T cells THINK trial in the USA